HRT for women with premature ovarian insufficiency: a comprehensive review.
Level 1 - systematic review of randomized trials
Systematic review of the literature with quality assessment conducted for clinical practice guideline development.
PubMed 30895225 · doi:10.1093/hropen/hox007
What was done
Authors conducted a systematic literature search in PubMed/MEDLINE and the Cochrane Library to identify studies assessing the indications, regimens, efficacy, and risks of hormone replacement therapy (estrogen, progestogens, and androgens) in women with premature ovarian insufficiency (loss of ovarian activity before age 40). Evidence was graded and summarized into evidence tables to inform the European Society of Human Reproduction and Embryology (ESHRE) clinical guideline.
What was found
The abstract provides no numerical data, effect sizes, or risk estimates. It reports that hormone replacement therapy is strongly recommended for managing vasomotor and genitourinary symptoms, preserving bone mineral density, and potentially mitigating long-term cardiovascular risk. The authors noted that clinical safety concerns associated with postmenopausal hormone therapy do not directly apply to physiological replacement in this younger population, but evidence defining optimal formulations, doses, or delivery routes is limited.
Why it matters
It reinforces that premature ovarian insufficiency represents premature hormone deficiency rather than natural menopause, justifying physiological replacement up to the typical age of natural menopause. It clearly separates the risk-benefit profile of hormone therapy in young women from the controversies surrounding older postmenopausal cohorts.
Limits
The abstract does not state the number of included studies or pooled participant numbers, and reports no quantitative outcomes. The review highlights major evidence gaps, including an absence of randomized controlled trials comparing transdermal versus oral estrogens, and limited empirical data regarding optimal dosing, life expectancy, quality of life, and neurological outcomes.
Cited by
- supports Premature ovarian failure is defined as going into ovarian failure before age 40.